NCT05930119 is a Phase 1 clinical trial of HMPL-453 in Intrahepatic Cholangiocarcinoma, sponsored by Hutchmed.

Who is sponsoring NCT05930119?

NCT05930119 is sponsored by Hutchmed.

What drugs are being tested in NCT05930119?

Interventions in NCT05930119: HMPL-453, Rabeprazole.

What condition does NCT05930119 study?

NCT05930119 studies Intrahepatic Cholangiocarcinoma.

Is NCT05930119 still recruiting?

NCT05930119 is currently completed. Last updated 6 September 2023.

Last reviewed 2023-09-06 · How we verify

NCT05930119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Completed Phase 1 Last updated 6 September 2023

What this trial tests

Phase 1 trial testing HMPL-453 in Intrahepatic Cholangiocarcinoma in 24 participants. Completed in 28 August 2023.

Timeline

17 March 2023

Primary endpoint
28 August 2023

28 August 2023

Quick facts

Lead sponsor	Hutchmed
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	17 March 2023
Primary completion	28 August 2023
Estimated completion	28 August 2023
Sites	1 location across China

Drugs / interventions tested

HMPL-453 — full drug profile →
Rabeprazole — full drug profile →

Conditions studied

Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →

Sponsor

Hutchmed — full company profile →

Who can join

Adults 18 to 55, any sex, with Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of HMPL-453

Trials testing the same drug.

NCT04353375 — HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma · Phase 2, PHASE3 · recruiting
NCT04290325 — HMPL-453 in Advanced Malignant Mesothelioma · Phase 2 · unknown
NCT03160833 — A Study of HMPL-453 in Patients With Advanced Solid Malignancies · Phase 1, PHASE2 · unknown

Other recruiting trials for Intrahepatic Cholangiocarcinoma

Currently open trials in the same condition.

NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
NCT06910722 — Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy · NA · recruiting
NCT07169734 — A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06664021 — Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperativ · Phase 2 · recruiting
NCT06505486 — GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC · recruiting

Other Hutchmed trials

Trials by the same sponsor.

NCT07409428 — A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL · Phase 3 · recruiting
NCT07396584 — HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07228247 — A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07348133 — Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets · Phase 1 · completed
NCT07331194 — Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05930119 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hutchmed
Last refreshed: 6 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05930119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing